University Department of Psychiatry, Warneford Hospital, Oxford, UK
Correspondence: Professor P.J. Cowen, University Department of Psychiatry, Warneford Hospital, Oxford OX37JX, UK
Declaration of interest None. Funding from the Medical Research Council.
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Aims To use the endocrine response to the selective 5-HT reuptake inhibitor, citalopram, to study brain 5-HT function in acute and recovered depressed subjects relative to healthy controls.
Method We used a double-blind, placebo-controlled design to measure the prolactin and cortisol responses to citalopram (10 mg intravenously) in patients with major depression, in unmedicated subjects recovered from depression and in healthy controls.
Results The prolactin responses to citalopram were blunted similarly in both acutely depressed and recovered subjects. The cortisol responses were blunted in the acutely depressed patients but not in the recovered subjects.
Conclusions Our data support the proposal that some aspects of impaired 5-HT neurotransmission may be trait markers of vulnerability to depression. The recovery of the cortisol response to citalopram may indicate resolution of hypothalamicpituitaryadrenal axis dysfunction.
![]() |
INTRODUCTION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
![]() |
METHOD |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
The mean (s.e.) ages of the three groups were similar (controls, 38.6 (3.0)
years; acute depression group, 44.5 (3.1) years; recovered depression group,
40.6 (3.1) years), as were their weights (controls, 70.1 (3.1) kg; acute
group, 75.9 (3.6) kg; recovered group, 72.2 (3.8) kg). Patients with acute
depression were drug-free for at least 3 months and had a mean (s.e.) score on
the Hamilton Rating Scale for Depression (HRSD;
Hamilton, 1960) of 20.9 (1.5)
and a Beck Depression Inventory (BDI; Beck
et al, 1961) score of 25.2 (3.3). Six subjects also met
the criteria for melancholic depression. The subjects who were recovered from
depression had been euthymic for at least 6 months and medication-free for at
least 3 months. Their HRSD score had to be 7
(Frank et al, 1991).
Their mean (s.e.) score on the HRSD was 1.5 (0.5) and on the BDI was 4.4
(1.3). Two in the recovered group and two in the acutely depressed group had a
past history of suicide attempts.
Neuroendocrine testing
All subjects were tested on two separate days in a double-blind, balanced
order, placebo-controlled design. The mean (s.e.) gap between the two tests
was 10 (2) days, with no significant difference between the groups (data not
shown). Subjects fasted after a light breakfast and came to the research unit
at 12.00 h. This time was chosen to avoid the sharp morning decline in plasma
prolactin and cortisol levels. An indwelling venous canula was inserted and
maintained with heparinised saline. Subjects were tested reclining and were
not allowed to sleep. After a 30-min rest period for removal of baseline
venous samples for prolactin and cortisol estimation, 10 mg citalopram
(diluted in 5 ml saline) or 5 ml saline was administered intravenously over 30
min. Blood sampling continued at 15-min intervals for a further 150 min. At
30-min intervals, subjects completed a 100-mm visual analogue rating scale
(VAS) for nausea. All female subjects were tested in the first
half of the menstrual cycle.
Biochemical measurements
Following blood collection, plasma was separated by centrifugation and
stored at -20°C. Plasma prolactin was measured using a standard
immunoradiometric assay (reagents provided by Netria, London, UK). The inter-
and intra-assay coefficients of variation of the prolactin assays over the
range encompassed by the standard curve were 5% and 1%, respectively. Cortisol
was analysed using radioimmunoassay (RIA) (reagents provided by Amersham
International, Amersham, and Bioclin, Cardiff, UK) with inter- and intra-assay
coefficients of variation over the range encompassed by the standard curve of
10% and 1%, respectively.
Statistical analysis
All data were analysed using SPSS for Windows (version 9.0). Prolactin and
cortisol responses to citalopram were analysed as area under the curve (AUC)
using the trapezoid method, with subtraction of baseline secretion
extrapolated from time zero. Change in AUC (AUC) was measured by
subtracting the AUC of prolactin and cortisol following placebo challenge from
the respective AUC following citalopram challenge. The
AUC data were
rank transformed in order to approximate satisfactorily to a normal
distribution and then subjected to standard parametric analyses
(Conover & Iman, 1981) with
univariate analysis of variance (ANOVA), where group (control,
acute depression and recovered depression) was the between-subject factor.
Gender, weight and age were added to the ANOVA as covariates. Significant
differences on the ANOVA were followed by post hoc unpaired
t-tests. In the text, for comprehensibility, the hormonal responses
are illustrated by the raw data rather than the rank-transformed results.
Correlations also were carried out on rank-transformed
AUC data using
Pearson's product moment. Baseline levels of prolactin and cortisol were
calculated for each group using the average of the baseline values (at time
zero) on the placebo and citalopram days and analysed by univariate ANOVA. The
VAS scores of nausea were measured as peak change from baseline and also were
analysed with an ANOVA.
![]() |
RESULTS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
There was no significant difference between mean (s.e.) baseline prolactin
levels across the three groups (F=0.60; d.f.=2.42; P=0.55):
controls, 174.1 (14.0) mU/l; acute group, 162.0 (16.9) mU/l; recovered group,
151.0 (15.3) mU/l. The ANOVA on the AUC prolactin data showed a
significant effect of group (F=3.53; d.f.=2.39, P=0.039).
Post hoc analysis showed that, relative to controls, prolactin
responses were decreased significantly in both the acute and recovered
depression groups, with no significant difference between these two groups
(Fig. 1). The covariates of
gender (F=0.003; d.f.=1.39; P=0.96), weight (F=1.1;
d.f.=1.39; P=0.31) and age (F=0.51; d.f.=1.39;
P=0.48) were not significant in the
AUC prolactin response.
|
There was no difference between baseline cortisol levels across the three
groups (F=1.618; d.f.=2.42; P=0.210): controls, 16.2 (1.9)
µg/100 ml; acute group, 17.2 (2.03) µg/100 ml; recovered group, 13.2
(0.73) µg/100 ml). The ANOVA of the AUC cortisol data showed a
significant effect of group (F=6.03; d.f.=2.39; P=0.005).
The post hoc analysis showed that, relative to controls, subjects
with acute depression had significantly blunted cortisol responses whereas the
recovered subjects did not. In addition, the responses of the recovered
subjects were significantly greater than those in the acute group
(Fig. 2). The covariates of
gender (F=0.47; d.f.=1.39; P=0.50), weight (F=0.01;
d.f.=1.35; P=0.95) and age (F=0.29; d.f.=1.39;
P=0.60) were not significant in the
AUC cortisol response.
|
There were no significant correlations between HRSD and BDI scores and
AUC cortisol or
AUC prolactin responses in either acute or
recovered subjects (all P values >0.05). Endocrine responses did
not differ in the small number of acutely depressed melancholic subjects
(n=6) compared with non-melancholic subjects. In all subjects
considered together there were no significant correlations between baseline
prolactin and
AUC prolactin responses or between baseline cortisol and
AUC cortisol responses. In addition, baseline cortisol did not correlate
with
AUC prolactin responses (all P values >0.5). However,
baseline cortisol and prolactin responses correlated with each other
(r=0.30, P=0.047) and the
AUC cortisol response
correlated with the
AUC prolactin response (r=0.46;
P=0.002). Finally, there was no correlation between peak nausea score
after citalopram and
AUC cortisol or
AUC prolactin response (all
P values >0.05).
![]() |
DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Citalopram as 5-HT neuroendocrine probe
Citalopram is a highly selective 5-HT reuptake inhibitor that, when
administered intravenously, produces dose-related increases in prolactin and
cortisol (Seifritz et al,
1996; Attenburrow et
al, 2001). Its neuroendocrine profile in this respect is the
same as that of other 5-HT reuptake inhibitors such as clomipramine and
indalpine (Laakmann, 1990).
The 5-HT releasing agent d-fenfluramine produces very similar changes
(Newman et al, 1998). Therefore, the ability of citalopram to increase plasma prolactin and cortisol
is likely to be mediated via acute increases in 5-HT neurotransmission in the
hypothalamus. The fact that prolactin and cortisol responses to citalopram
correlated significantly with each other supports the proposal that they are
mediated by a common (probably serotonergic) mechanism.
The most appropriate intravenous dose of citalopram for neuroendocrine challenge has not yet been established clearly. Other studies of citalopram in depressed and healthy subjects have used doses of 20 mg (Seifritz et al, 1996; Kapitany et al, 1999) but in healthy volunteers we found that doses of 5 mg and above produce significant increases in prolactin and cortisol relative to placebo (Attenburrow et al, 2001). We therefore chose a dose of 10 mg as likely to represent a reasonable balance between tolerability and the production of reliable endocrine responses. The identity of the post-synaptic 5-HT receptors that mediate citalopram-induced prolactin and cortisol release has not yet been determined. Our preliminary work suggests that they are unlikely to be of the 5-HT2A/2C receptor subtype (Attenburrow et al, 2001).
Serotonin neuroendocrine responses in acute depression
Our findings with citalopram are consistent with a large body of data
indicating that the endocrine responses to 5-HT challenges, particularly those
that act via facilitation of presynaptic 5-HT function, are reliably blunted
in patients with acute major depression
(Cowen, 1998). In particular,
our data are consistent with studies that have found blunted prolactin
responses to the 5-HT reuptake inhibitor clomipramine
(Anderson et al, 1992;
Golden et al, 1992),
as well as one previous investigation using 20 mg of intravenous citalopram
(Kapitany et al,
1999). In the latter investigation, citalopram-induced cortisol
release was not decreased significantly in patients with depression relative
to healthy controls, although a trend in this direction was apparent.
Less-consistent effects in depression have been noted with the prolactin response to the 5-HT releasing agent fenfluramine, where blunted responses may be more apparent in subjects with melancholic depression and in those with impulsive personality traits (Cowen, 1998). This latter observation suggests that features other than current major depression may contribute to blunted endocrine responses to 5-HT challenge, a notion supported by our findings in subjects recovered from depression (see below).
The nature of the impairment in brain 5-HT pathways that is responsible for the blunted endocrine responses to presynaptic 5-HT challenge in acute depression has not been established clearly. However, brain imaging studies have identified decreased numbers of post-synaptic 5-HT1A (Sargent et al, 2000) and 5-HT2A receptors (Yatham et al, 2000) in patients with major depression. Perhaps most pertinent to challenge studies with 5-HT reuptake inhibitors are reports of decreased availability of 5-HT reuptake sites in mid-brain and brain-stem regions of patients with depression (Malison et al, 1998; Willeit et al, 2000). These abnormalities could contribute to the decreased functional responses to 5-HT challenge identified by neuroendocrine tests.
Serotonin neuroendocrine function in subjects recovered from
depression
We found that the prolactin response to citalopram remained blunted in
subjects who had recovered from depression and were off medication. Because
people who have previous episodes of depression are at high risk of future
episodes (Kendler et al,
1993), it is possible that blunted 5-HT-mediated prolactin release
may be a trait marker indicating vulnerability to major depression. It is
possible also that blunted 5-HT-mediated prolactin release could be a
consequence of having experienced an episode of major depression.
To resolve this issue, future investigations will need to study larger numbers of subjects and identify as accurately as possible in each individual the number of previous depressive episodes as well as the length of symptomatic remission. Other studies have suggested that altered 5-HT function may be linked to particular clinical correlates, such as liability to suicidal and aggressive behaviour (Kavoussi et al, 1997). Again, larger studies will be needed to explore this kind of possibility. However, in our study the small number of subjects who had made suicide attempts suggest that this may not be a prominent factor underlying blunted prolactin responses to citalopram. Recent weight loss also may complicate interpretation of endocrine responses to 5-HT challenge (Cowen, 1998). However, again this is unlikely to be a factor in the blunted prolactin responses in subjects recovered from depression, who did not describe any recent appetite change or weight loss on the clinical rating scales.
Our data are consistent with two of the three studies that have examined prolactin responses to fenfluramine in unmedicated subjects who had recovered from depression (Coccaro et al, 1987; Shapira et al, 1993; Flory et al, 1998). However, in two previous studies we have found that recovered patients have normal prolactin responses to the 5-HT precursor L-tryptophan (Upadhyaya et al, 1991; Smith et al, 2000). This suggests that some 5-HT abnormalities in depression are reversible with recovery, whereas others are not. Specifically, the prolactin response to L-tryptophan appears to be mediated via post-synaptic 5-HT1A receptors (Cowen, 1998), whereas the prolactin responses to citalopram are not attenuated by penbutolol, a ß-adrenoceptor antagonist with 5-HT1A receptor antagonist properties (further details available from the author upon request).
Unlike citalopram-induced prolactin release, the cortisol responses in euthymic patients did show significant recovery compared with the acute depressed state. This again may reflect differential recovery between distinct 5-HT sub-systems. Another possibility is that blunted cortisol responses to 5-HT challenge are, in fact, partly dependent on the abnormal cortisol regulation often associated with the depressed state. The function of the hypothalamicpituitary-adrenal axis shows extensive recovery with clinical remission (Zobel et al, 1999) and this could account for the relative normalisation of citalopram-induced cortisol release in recovered patients.
In conclusion, our findings confirm that acute major depression is associated with blunted 5-HT-mediated prolactin release and that this abnormality persists into clinical remission. Further studies will be needed to establish whether this represents a trait marker of vulnerability to depression and, if so, whether its origin is predominantly genetic or environmental.
![]() |
Clinical Implications and Limitations |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
LIMITATIONS
![]() |
ACKNOWLEDGMENTS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Anderson, I. M., Ware, C.J., Da Roza Davis, J.M., et al (1992) Decreased 5-HT-mediated prolactin release in major depression. British Journal of Psychiatry, 160, 372-378.[Abstract]
Attenburrow, M. J., Mitter, P. R., Whale, R., et al (2001) Low-dose citalopram as a 5HT neuroendocrine probe. Psychopharmacology, 155, 323-326.[CrossRef][Medline]
Beck, A. T., Ward, C. H., Mendelson, M., et al (1961) An inventory for measuring depression. Archives of General Psychiatry, 4, 561-571.[Medline]
Coccaro, E. F., Siever, L. J., Klar, H., et al (1987) Diminished prolactin responses to repeat fenfluramine challenge in man. Psychiatry Research, 22, 257-259.[CrossRef][Medline]
Conover, W. J. & Iman, R. I. (1981) Rank transformations as a bridge between parametric and non-parametric statistics. American Statistician, 35, 124-127.
Cowen, P. J. (1998) Neuroendocrine challenge tests: what can we learn from them? Methods in Neuroendocrinology (ed. L. D. Van der Kar), pp. 205-223. Boca Raton, FL: CRC Press.
First, M. B., Spitzer, R. L., Gibbon, M., et al (1997) Structural Clinical Interview for DSM-IV Axis I Disorders Clinical Version (SCID-CV). Washington, DC: American Psychiatric Press.
Flory, J. D., Mann, J. J., Manuck, S. B., et al (1998) Recovery from major depression is not associated with normalisation of serotonergic function. Biological Psychiatry, 43, 320-326.[CrossRef][Medline]
Frank, E., Prien, R. F., Jarrett, R. B., et al (1991) Conceptualisation and rationale for consensus definitions of terms in major depressive disorder: remission, recovery, relapse, and recurrence. Archives of General Psychiatry, 48, 851-855.[Abstract]
Golden, R. N., Ekstrom, D., Brown, T. M., et al (1992) Neuroendocrine effects of intravenous clomipramine in depressed patients and healthy subjects. American Journal of Psychiatry, 149, 1168-1175.[Abstract]
Hamilton, M. (1960) A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry, 23, 56-62.[Medline]
Joubert, A. F., Sanchez, C. & Larssen, F. (2000) Citalopram. Human Psychopharmacology, 15, 439-451.[CrossRef][Medline]
Kapitany, T., Schindl, M., Schindler, S. D., et al (1999) The citalopram challenge test in patients with major depression and healthy controls. Psychiatry Research, 88, 75-88.[CrossRef][Medline]
Kavoussi, R., Armstead, P. & Coccaro, E. (1997) The neurobiology of impulsive aggression. Psychiatric Clinics of North America, 20, 395-403.[Medline]
Kendler, K. S., Kessler, R. C., Neale, M. C., et al (1993) The prediction of major depression in women: toward an integrated etiologic model. American Journal of Psychiatry, 150, 1139-1148.[Abstract]
Laakmann, G. (1990) Psychopharmacoendocrinology and Depression Research. Heidelberg: Springer-Verlag.
Malison, R. T., Price, L. H., Berman, R., et al (1998) Reduced brain serotonin transporter availability in major depression as measured by [1231]-2ß- carbomethoxy-3ß-(4-iodophenyl)tropane and single photon emission computed tomography. Biological Psychiatry, 44, 1090-1098.[CrossRef][Medline]
Newman, M. E., Shapira, B. & Lerer, B. (1998) Evaluation of central serotonergic function in affective and related disorders by the fenfluramine challenge test: a critical review. International Journal of Psychopharmacology, 1, 49-69.
Sargent, P. A., Kjaer, K. H., Bench, C. J., et al
(2000) Brain serotonin IA receptor binding measured by
positron emission tomography using IIC WAY 100635. Archives of
General Psychiatry, 57,
174-180.
Seifritz, E., Baumann, P., Muller, M. J., et al (1996) Neuroendocrine effects of a 20-mg citalopram infusion in healthy males. A placebo-controlled evaluation of citalopram as 5-HT function probe. Neuropsychopharmacology, 14, 253-263.[CrossRef][Medline]
Shapira, B., Cohen, J., Newman, M. E., et al (1993) Prolactin response to fenfluramine and placebo challenge following maintenance pharmacotherapy withdrawal in remitted depressed patients. Biological Psychiatry, 33, 531-535.[CrossRef][Medline]
Smith, K. A., Williams, C. & Cowen, P. J.
(2000) Impaired regulation of brain serotonin function during
dieting in women recovered from depression. British Journal of
Psychiatry, 176,
72-75.
Upadhyaya, A., Pennell, I., Cowen, P. J., et al (1991) Blunted growth hormone and prolactin response to L-tryptophan in depression: a state dependent abnormality. Journal of Affective Disorders, 21, 213-218.[CrossRef][Medline]
Willeit, M., Praschak, R. N., Neumeister, A., et al (2000) [(123)I]-ß-CIT SPECT imaging shows reduced brain serotonin transporter availability in drug free depressed patients with seasonal affective disorder. Biological Psychiatry, 47, 482-489.[CrossRef][Medline]
Yatham, L. N., Liddle, P. F., Shiah, I. S., et al
(2000) Brain serotonin 2 receptors in major depression: a
positron emission tomography study. Archives of General
Psychiatry, 57,
850-858.
Zobel, A. W., Yassouridis, A., Frieboes, R. M., et al
(1999) Prediction of medium-term outcome by cortisol response
to the combined dexamethasone-CRH test in patients with remitted depression.
American Journal of Psychiatry,
156,
949-951.
Received for publication April 2, 2001. Revision received August 15, 2001. Accepted for publication September 27, 2001.
Related articles in BJP: